ClaimsFiler reminds investors that they have until August 10, 2026 to file lead plaintiff applications in a securities class action lawsuit against Erasca, Inc. if they purchased or otherwise acquired the Company’s securities between January 14, 2025 and April 26, 2026. The lawsuit, pending in the United States District Court for the Southern District of California, alleges that Erasca and certain executives failed to disclose material information, including that preclinical data for its ERAS-0015 product was based on improper comparisons to Revolution Medicines, Inc. and placed Erasca at risk of violating patent and trade secret protections. The case is Cheng v. Erasca, Inc., No. 26-cv-03481.
Erasca IncSecurities class action lawsuit alleging failure to disclose improper preclinical data comparisons and patent/trade secret violations.